Login to Your Account

Can a pill tackle type 1 diabetes? IM Therapeutics looks to find out

By Michael Fitzhugh
Staff Writer

Thursday, November 9, 2017

Immunomolecular (IM) Therapeutics LLC, a company created to develop small-molecule therapies for the treatment of genetically defined autoimmune diseases, has revealed its lead candidate, an immunotherapy for type 1 diabetes, IMT-002

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription